The Zepbound dose schedule is a stepwise titration: start at 2.5 mg once weekly for 4 weeks, then escalate by 2.5 mg every 4 weeks until reaching one of three maintenance doses—5 mg, 10 mg, or 15 mg. The FDA-approved label designs this pace specifically to limit GI side effects while delivering the weight loss seen in trials.
The Full Titration Calendar
| Weeks | Weekly Dose | Purpose |
|---|---|---|
| 1–4 | 2.5 mg | Starter dose (not maintenance) |
| 5–8 | 5 mg | First maintenance option |
| 9–12 | 7.5 mg | Titration step |
| 13–16 | 10 mg | Second maintenance option |
| 17–20 | 12.5 mg | Titration step |
| 21+ | 15 mg | Maximum maintenance |
Per the FDA prescribing information, each dose should be maintained for at least 4 weeks before advancing.
Why the Schedule Matters
Tirzepatide (Zepbound’s active ingredient) activates GLP-1 and GIP receptors, slowing gastric emptying and reducing appetite. Those same effects drive GI side effects—nausea, diarrhea, constipation—especially after each dose bump. Titrating slowly lets receptor signaling adapt, which is why most people tolerate 15 mg better after reaching it slowly than if they started there.
How to Take Zepbound
Zepbound is a once-weekly subcutaneous injection. Key practical points:
- Choose one day of the week and inject the same day each week.
- Rotate injection sites: abdomen, thigh, or upper arm.
- Use prefilled single-dose pens exactly as labeled.
- Store refrigerated at 36–46°F; pens can be at room temperature up to 21 days.
- Inject at the same time of day if possible, but timing is flexible.
Weight Loss Timeline
Appetite suppression usually starts within 1–2 weeks. Measurable weight loss typically appears by weeks 4–8. In the SURMOUNT-1 trial, 72-week results were:
- 5 mg: ~15.0% body weight lost
- 10 mg: ~19.5% body weight lost
- 15 mg: ~20.9% body weight lost
- Placebo: ~3.1%
Expect plateaus between dose increases. Progress is not linear; months 1–3 often see rapid loss, then the curve flattens until the next dose bump.
Side Effects to Expect
Common (10%+)
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Injection site reactions
- Fatigue
Severity peaks in the first week after a dose increase, then subsides. Smaller meals, protein first, hydration, and avoiding high-fat foods all help.
Less Common but Serious
- Pancreatitis—severe abdominal pain, call your clinician
- Gallbladder disease
- Kidney injury from dehydration
- Severe hypoglycemia (with insulin or sulfonylureas)
- Allergic reactions
The FDA boxed warning lists thyroid C-cell tumors as a concern from rat studies. Do not use with a personal or family history of medullary thyroid carcinoma or MEN 2.
Handling Missed Doses
If you miss a dose and it has been within 4 days, take it as soon as you remember and resume the normal weekly day. If more than 4 days have passed, skip that dose and take the next one on schedule. Never double up. If you miss more than 3 consecutive weeks, your clinician may restart titration at a lower dose.
Who Can Take Zepbound
FDA-approved for adults with:
- BMI of 30 or higher, OR
- BMI of 27 or higher plus a weight-related condition (hypertension, type 2 diabetes, dyslipidemia, sleep apnea, cardiovascular disease)
In 2024, the FDA also approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. Those with prediabetes often qualify based on BMI and comorbidities—see our treatment hub for details.
Zepbound and Prediabetes
While not approved for prediabetes specifically, Zepbound’s weight loss translates to large improvements in A1C and fasting glucose. The CDC’s Diabetes Prevention Program shows 5–7% weight loss cuts diabetes progression by 58%. Many Zepbound users exceed that benchmark. Our prediabetes 101 hub covers how medication and lifestyle change work together.
Stopping or Switching
Abrupt discontinuation typically leads to significant weight regain—SURMOUNT-4 showed about two-thirds of lost weight returned within 52 weeks of stopping. Plan transitions carefully with your clinician, ideally with intensified lifestyle support before tapering.
Switching from semaglutide (Wegovy/Ozempic) to Zepbound usually restarts at 2.5 mg; your clinician will advise.
Cost and Access Reality
List price is approximately $1,060 per month. Commercial insurance coverage is inconsistent; savings cards bring eligible patients to $25 monthly. Medicare typically does not cover weight-loss drugs. In 2024, Lilly introduced self-pay vials at lower prices for cash payers.
The Bottom Line
The Zepbound dose schedule is built for steady, tolerable progress—2.5 mg starter, then monthly 2.5 mg increases to 5, 10, or 15 mg maintenance. Stick to the pace, watch for GI symptoms in the first week after increases, and partner with your clinician on dose decisions. Sustainable results depend on long-term use paired with lifestyle changes.
This article is educational and not a substitute for personalized medical advice. Always consult your healthcare provider about symptoms, testing, and treatment.
